BioVectra

Adapting, Partnering, and Innovating: Insights from CPhI Frankfurt

How CDMOs are navigating uncertainty, forging partnerships, and embracing flexibility.

Agilent to Buy Canadian CDMO Biovectra for $925 Million

Santa Clara, CA-based Agilent Technologies has signed a definitive agreement to acquire specialized contract development and manufacturing organization Biovectra from H.I.G. Capital in a move to expand its end-to-end biopharma solutions.

News

Mallinckrodt Sells BioVectra to H.I.G. Capital

Top-Feature

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

INOSIM GmbH

Predictive Simulation in Pharma Production

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

From Catalogue to Collaboration

Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

Agilent Technologies Inc.

CHEManager International c/o Wiley-VCH GmbH